LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
Nuformix PLC (NFX.L) Notice of Allowance of Patent in US
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,
Nuformix PLC (NFX.L) Project update – Progress on NXP002 and NXP004
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, post-fund raising, it has started the planned studies on